| Title | DBA/2 Mouse as an Animal Model for Anti-influenza Drug Efficacy Evaluation |
|---|---|
| Author | Jin Il Kim, Sehee Park, Sangmoo Lee, Ilseob Lee, Jun Heo, Min-Woong Hwang, Joon-Yong Bae, Donghwan Kim, Seok-Il Jang, Mee Sook Park, and Man-Seong Park* |
| Address | Department of Microbiology, Center for Medical Science Research, College of Medicine, Hallym University, Chuncheon 200-702, Republic of Korea |
| Bibliography | Journal of Microbiology, 51(6),866–871, 2013, |
| DOI | 10.1007/s12275-013-3428-7 |
| Key Words | adaptation, animal model, antiviral, DBA/2 mouse,influenza virus |
| Abstract | Influenza viruses are seasonally recurring human pathogens. Vaccines and antiviral drugs are available for influenza. However, the viruses, which often change themselves via antigenic drift and shift, demand constant efforts to update vaccine antigens every year and develop new agents with broad-spectrum antiviral efficacy. An animal model is critical for such efforts. While most human influenza viruses are unable to kill BALB/c mice, some strains have been shown to kill DBA/2 mice without prior adaptation. Therefore, in this study, we explored the feasibility of employing DBA/2 mice as a model in the development of anti-influenza drugs. Unlike the BALB/c strain, DBA/2 mice were highly susceptible and could be killed with a relatively low titer (50% DBA/2 lethal dose = 102.83 plaque-forming units) of the A/ Korea/01/2009 virus (2009 pandemic H1N1 virus). When treated with a neuraminidase inhibitor, oseltamivir phosphate, infected DBA/2 mice survived until 14 days postinfection. The reduced morbidity of the infected DBA/2 mice was also consistent with the oseltamivir treatment. Taking these data into consideration, we propose that the DBA/2 mouse is an excellent animal model to evaluate antiviral efficacy against influenza infection and can be further utilized for combination therapies or bioactivity models of existing and newly developed anti-influenza drugs. |